Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Jackson Finl, Lowers Price Target to $33

Morgan Stanley Maintains Equal-Weight on Jackson Finl, Lowers Price Target to $33

Morgan Stanley analyst Nigel Dally maintains Jackson Finl (NYSE:JXN) with a Equal-Weight and lowers the price target from $40 to $33.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Morgan Stanley analyst Nigel Dally maintains Jackson Finl (NYSE:JXN) with a Equal-Weight and lowers the price target from $40 to $33.

New Jersey Wants Social Equity To Be Part Of Its Cannabis Program, Are Big Weed Companies On Board?

By Joana Scopel

October 7, 4:39 PM

Even though marijuana sales are legal in New Jersey, members of the Cannabis Regulatory Commission (CRC) have made it clear that they are not satisfied with how things are shaking out. Municipal rejection of dispensaries, rising real estate prices and lack of

CURLF

B of A Securities Downgrades Sylvamo to Neutral, Raises Price Target to $58

By Benzinga Newsdesk

December 15, 8:50 AM

B of A Securities analyst George Staphos downgrades Sylvamo (NYSE:SLVM) from Buy to Neutral and raises the price target from $56 to $58.

SLVM

Foghorn Prices $110M Registered Direct Offering Of 12,743,039 Common Stock At A Price Of $5.51 Per Share And Pre-Funded Warrants To Purchase Up To An Aggregate Of 7,220,794 Shares Of Its Common Stock At A Price Of $5.5099 Per Pre-Funded Warrant

By Benzinga Newsdesk

May 20, 8:02 AM

Foghorn Therapeutics Inc. ("Foghorn") (NASDAQ:FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and

FHTX